Advertisement
Advertisement
TLSA
Tiziana Life Sciences Ltd. Common Shares
0.90
USDSponsored
-0.05
-4.77%
Oct 29, 15:59 UTC -4
Closed
Pre-Market
0.93
+0.03
+2.80%
Tiziana Life Sciences Ltd. Common Shares (TLSA) Earnings
TLSA Earnings Reports
Positive Surprise Ratio
TLSA beat 0 of 1 last estimates.
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Tiziana Life Sciences Ltd. Common Shares earnings per share and revenue
On Oct 16, 2026, TLSA reported earnings of -0.10 USD per share (EPS) for Q2 26, missing the estimate of -0.08 USD, resulting in a -22.55% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a -3.81% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
NovoCure Limited Ordinary Shares
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.09
Surprise
+63.88%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.14
Actual
$0.04
Surprise
+128.27%
Gilead Sciences Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.24
Actual
$2.54
Surprise
+13.66%
Bristol-Myers Squibb Co.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.20
Actual
$1.35
Surprise
+11.66%
Illumina Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.38
Actual
$1.44
Surprise
+4.18%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Incyte Genomics Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$3.92
Actual
-$3.60
Surprise
+8.33%
Exelixis Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.81
Actual
$0.94
Surprise
+15.64%
Kymera Therapeutics, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$1.29
Actual
-$1.32
Surprise
-2.17%
Ligand Pharmaceuticals Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.42
Actual
$2.67
Surprise
+9.91%
FAQ
What were Tiziana Life Sciences Ltd. Common Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Tiziana Life Sciences Ltd. Common Shares reported EPS of -$0.10, missing estimates by -22.55%, and revenue of --, -- -- expectations.
How did the market react to Tiziana Life Sciences Ltd. Common Shares's Q2 2026 earnings?
The stock price moved down -3.81%, changed from $1.05 before the earnings release to $1.01 the day after.
When is Tiziana Life Sciences Ltd. Common Shares expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Tiziana Life Sciences Ltd. Common Shares's next earnings report?
Based on --
analysts, Tiziana Life Sciences Ltd. Common Shares is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.